Peter Lio, MD

This segment of Lio's RAD Conference interview in Nashville highlights the growing number of therapeutics and an increasingly personalized approach.

Peter Lio, MD, spoke at the RAD 2026 conference about the upcoming AAD pediatric guidelines for atopic dermatitis.

As dermatology patients enter clinical visits with information from social media, online forums, and AI inquiries, clinicians are juggling new concerns.

Topical steroid withdrawal remains a controversial topic in the dermatology field, given the lack of necessary data.

This Fall Clinical Dermatology Conference interview features Peter Lio, MD, discussing takeaways from several of his sessions at the meeting.

This interview with Peter Lio, MD, at RAD 2025 provides several insights into the topic of topical steroid withdrawal versus atopic dermatitis and what the distinction may be.

In this interview at RAD 2025, Peter Lio, MD, highlighted whether precision medicine is a possibility in the near future in the atopic dermatitis management space.

This interview features a discussion with Lio regarding pediatric atopic dermatitis and the connection between caregivers, patients, and providers.

Peter Lio, MD, discusses the value of hyperfocused meetings such as RAD and what sessions he is most looking forward to at RAD 2025.

Panelists discuss whether a treatment switch would be considered for a patient with 75% improvement in atopic dermatitis, weighing the benefits of continued treatment versus the potential for further improvement with a different therapy.

Panelists discuss how they define treatment non-responders in atopic dermatitis (AD), focusing on factors such as lack of significant improvement in symptoms, inadequate response to therapy, or failure to achieve treatment goals despite proper adherence and adjustments.

Panelists discuss the limited data on atopic dermatitis (AD) treatments in patients with skin of color, highlighting findings from other studies and real-world data to better understand treatment efficacy and safety in this diverse patient population.

Panelists discuss switching from dupilumab to other IL-13 inhibitors in atopic dermatitis (AD), reviewing real-world data (RWD) on the effectiveness, safety, and patient outcomes associated with these treatments.

Panelists discuss the safety of biologics in atopic dermatitis (AD), reviewing current understanding of their safety profiles, including long-term data, adverse events, and the overall risk-benefit analysis for patients using these agents.

Panelists discuss the frequency of combination therapy use in managing atopic dermatitis, highlighting its role in enhancing treatment efficacy and addressing multifactorial aspects of the disease in their patient population.

Panelists discuss when to consider switching to another biologic or exploring a different mechanism of action in atopic dermatitis treatment, focusing on factors like inadequate response, adverse effects, or the need for more targeted therapy to optimize patient outcomes.

Panelists discuss the maintenance of treatment efficacy in the lebrikizumab clinical trial, highlighting data on sustained improvement in atopic dermatitis symptoms over time and the long-term effectiveness of the treatment.

Panelists provide an overview of the latest efficacy and safety data for IL-13–targeting therapies in atopic dermatitis (AD), including recently presented data on dupilumab, lebrikizumab, and tralokinumab, focusing on their effectiveness in symptom reduction and safety profiles across patient populations.

Panelists discuss the differences between the 3 FDA-approved IL-13–targeting agents for atopic dermatitis (AD)—dupilumab, tralokinumab, and lebrikizumab—and how these differences in their mechanisms of action might impact their effectiveness in targeting the disease and addressing various patient needs.

Panelists discuss recent guideline changes regarding advanced systemic therapy in atopic dermatitis (AD), focusing on when to transition a patient to systemic agents and when biologics should be considered for the treatment of moderate to severe AD.

Panelists discuss how treatments for atopic dermatitis impact patients' quality of life, focusing on improvements in symptoms, daily functioning, and emotional well-being with different therapeutic options.

Panelists discuss how the standard of care in atopic dermatitis (AD) has evolved with recent advances in treatment, highlighting the use of assessment tools and scoring systems in clinical practice, and compare real-world outcomes with those seen in clinical trials for AD treatments.

Panelists discuss how recent treatment approvals for atopic dermatitis (AD), including new biologics and systemic therapies, are reshaping management, and emphasize how patient factors, such as severity, comorbidities, and treatment history, guide treatment selection in AD.

Panelists discuss how to confirm the diagnosis of atopic dermatitis (AD) when in doubt, emphasizing the importance of clinical evaluation, family history, and skin testing, and share strategies for approaching adult patients with new-onset AD, including thorough patient history and targeted management.

Panelists discuss how the clinical heterogeneity of Atopic Dermatitis (AD) presents diagnostic challenges, with varying criteria for pediatric and adult-onset AD, highlighting the need for age-specific approaches to accurately diagnose and treat the condition.

Medical experts share their final thoughts on the future of atopic dermatitis treatment with oral systemic agents.

Medical experts review the data on the use of oral JAK inhibitors for maintenance and rescue treatments in atopic dermatitis.

Medical experts discuss how often patients with atopic dermatitis request treatment breaks, their monitoring approach during these breaks, and how to educate and counsel patients about treatment breaks and rescue treatments, including identifying suitable candidates.

Medical experts rate dermatologists’ comfort with switching to JAK inhibitors and describe how frequently to switch patients from biologics to JAK inhibitors, including their treatment strategy for this population.

Medical experts discuss disease control with abrocitinib or upadacitinib in patients previously taking dupilumab and explain the circumstances under which they would switch a patient to a JAK inhibitor.